Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months

• Published in: Journal of bone and mineral research 2008-08, Vol.23 (8), p.1304-1308
• Main Authors: Bolland, Mark J, Grey, Andrew B, Horne, Anne M, Briggs, Simon E, Thomas, Mark G, Ellis‐Pegler, Rod B, Callon, Karen E, D Gamble, Greg, Reid, Ian R
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; BMD; Bone and Bones - drug effects; Bone and Bones - metabolism; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - pharmacology; bone turnover; Diphosphonates - administration & dosage; Diphosphonates - pharmacology; Dose-Response Relationship, Drug; Drug Administration Schedule; Fundamental and applied biological sciences. Psychology; HIV; HIV Infections - physiopathology; Human immunodeficiency virus; Humans; Imidazoles - administration & dosage; Imidazoles - pharmacology; Injections, Intravenous; Male; Middle Aged; osteoporosis; Placebos; Skeleton and joints; Time Factors; Vertebrates: osteoarticular system, musculoskeletal system; zoledronate
• ISSN: 0884-0431; 1523-4681
• DOI: 10.1359/jbmr.080312

The duration of the antiresorptive effects of the intravenous bisphosphonate, zoledronate, is not known. Recently, we reported that two annual 4‐mg doses of zoledronate suppressed bone turnover and increased BMD in HIV‐infected men over 24 mo. We set out to determine the persistence of these effects after two doses of zoledronate. Thirty‐three HIV‐infected men who completed a randomized trial of 4 mg annual zoledronate (n = 17) or placebo (n = 16) were studied for a further 12 mo, during which time no skeletal therapy was administered. Participants received calcium (400 mg/d) and vitamin D supplements (50,000 IU/mo) for the first 24 mo of the study only. Biochemical markers of bone turnover and BMD were measured every 6 mo. Bone turnover markers were stably suppressed at 24 and 36 mo (12 and 24 mo after the second annual dose of zoledronate, respectively). There were no significant within‐group changes in urine N‐telopeptide, serum C‐telopeptide, and osteocalcin between 24 and 36 mo (p > 0.07), and at each time point, each of the turnover markers was significantly lower in the zoledronate group. There were also no significant between‐group differences in the changes in BMD at each site between 24 and 36 mo (p > 0.5), and at each time point, BMD at each site was significantly higher in the zoledronate group. These results suggest that the antiresorptive effects of zoledronate last >12 mo and raise the possibility that zoledronate could be administered less frequently than annually. Randomized trials that address this issue should be performed.